Trelegy Ellipta 100 ug/1

Trelegy Ellipta 100 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Trelegy Ellipta 100 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines three active ingredients to help manage symptoms such as wheezing, shortness of breath, and coughing. This inhaler is not intended for the relief of acute bronchospasm or asthma attacks. Patients often ask, 'What is Trelegy Ellipta used for?' It is designed to improve lung function and reduce the frequency of exacerbations in COPD patients.

Common effects of Trelegy Ellipta 100 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience a taste alteration or hoarseness. These effects are generally mild and temporary. It's important to consult a healthcare provider if any effects persist or worsen.

Trelegy Ellipta 100 ug/1 should be used as directed by a healthcare provider. It is important to rinse your mouth after each use to reduce the risk of throat irritation and oral candidiasis. Patients with a history of asthma should use this inhaler with caution. Always store the inhaler at room temperature and keep it out of reach of children.

Trelegy Ellipta 100 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking. Additionally, the use of alcohol or other respiratory medications should be discussed with a healthcare provider to avoid potential interactions.